Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Covance 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Covance 1Q11

Early Development revenues were $224.0 million (+9%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance

1Q Revenues: $502.0 million (+4%)

1Q Earnings: $32.7 million (-16%)

Comments: Early Development revenues were $224.0 million (+9%). Toxicology performance continued to improve in the quarter. Late-Stage Development revenues were flat at $278.0 million. Improved clinical development was partially offset by lower central lab revenues. The company’s backlog at March 31, 2011 grew 31% to $6.3 billion. Foreign exchange positively impacted backlog by approximately $127 million. Adjusted net orders (adjusted for dedicated capacity contracts) were $564 million in the quarter. Restructuring costs were $5.9 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics